Immunoglobulin E specific for Alnus rhombifolia pollen allergens (IgE (Alnus rhombifolia))

Immunoglobulin E (IgE) antibodies specific for Alnus rhombifolia (White Alder) pollen allergens are central components of the allergic immune response in sensitized individuals. These antibodies are produced by B cells following exposure to Alnus rhombifolia pollen and subsequently bind to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils (Galli & Tsai, 2012). When the individual is re-exposed to the pollen, allergens such as Aln r 1 cross-link the receptor-bound IgE, triggering the immediate release of inflammatory mediators like histamine and leukotrienes (Allergome, 2024). This physiological process leads to the clinical manifestations of seasonal allergic rhinitis and allergic asthma. Therapeutic interventions targeting this pathway include the monoclonal antibody Omalizumab, which binds to the Fc region of free IgE, thereby preventing its attachment to mast cells and basophils (Genentech, 2023). Additionally, allergen-specific immunotherapy (AIT) utilizes Alnus rhombifolia extracts to desensitize the immune system, often by promoting the production of blocking IgG4 antibodies that compete with IgE for allergen binding.

Other names

White Alder pollen-specific IgEAnti-Aln r IgEAlnus rhombifolia-specific Immunoglobulin EAlder pollen-specific IgE

Neutralization of free IgE to prevent binding to FcεRI receptors on effector cells; downregulation of receptor expression; induction of immune tolerance via allergen-specific immunotherapy.